2-[4-(β-D-Glucopyranuronosyloxy)phenyl]-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-6-yl β-D-Glucopyranosiduronic Acid
making the control of this modification crucial for the development of effective biopharmaceuticals
1-[[[(4-Aminophenyl)sulfonyl](2-Methylpropyl)aMino]Methyl]-2-[[[[(3R
/ α-D-LacNAc-Propyl-Amine / LacNAc-α-C3-NH2
3-Aminopropyl (Neu5Acα2-6Gal β1-4GlcNAc)
GP100080: MUC1(126-149)-Tn(130,131,144) Pack Size:1 mg 2-[4-(β-D-Glucopyranuronosyloxy)phenyl]-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-6-yl β-D-Glucopyranosiduronic AcidC119H188N32O47 2818. 95 MUC1 (UniProt ID P15941) synthetic glycopeptide fragment (Pro126 Gly149; UniProt position 126 149, aa length 24) from the tandem repeat (TR) region of the MUC1 protein. The fragment contains tumor associated carbohydrate antigen (TACA), Tn antigen, O glycosylation ( GalNAc) at Ser130, Thr131 and Thr144. The C terminus is carboxylic acid. MUC1(126 149) Tn(130,131,144) Mucin1; Synthetic MUC 1 (tri Tn) glycopeptide